While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed.
Traci Medford-Rosow
Advertisement
Articles by Traci Medford-Rosow
On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case.
Advertisement
Latest Updated Articles
- FTC v. Actavis: The Wrong End of the Telescope
Published: March 25th 2014 | Updated:
Is the Hatch-Waxman System Broken?Published: January 6th 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
